Penny stock under Rs 40: This small-cap EPC company bags order worth Rs 141 crore!
Shares of the company have given about 7 per cent in today’s trade.
On April 12, 2023, BL Kashyap and Sons Limited informed in the exchange filing that the company has secured new order aggregating to Rs 141 crore from National High-Speed Rail Corporation Limited. The order involves the construction of training institute buildings at Vadodara. The order is to be completed in 24 months.
Earlier, on March 27, 2023, the company secured another order worth Rs 313 crore from Railway Land Development Authority. The total order book of the company as of date stands at Rs 2522 crores.
BL Kashyap and Sons Ltd is an EPC company engaged in the business of Construction of buildings high-rise residential and commercial complexes, IT Parks, institutional buildings, etc.
Today, the stock opened at Rs 33.30, with a high and low of Rs 35.14 and Rs 33.30. The stock closed trading at Rs 35.14, up by 7.23 per cent.
In the last one year, the shares of the company have given more than 25 per cent returns and on a YTD basis, the stock has given about 9 per cent returns.
The stock has a 52-week high of Rs 38.30 and a 52-week low of Rs 16.85. The company has a ROCE of 9.65 per cent and an ROE of 4.54 per cent, with a market capitalisation of Rs 798 crore.
Related articles
-
Penny stock under Rs 10: Company Expands Global Footprint with Two New Customers in South Africa; Expecting USD 1 Million Annual Revenue from New Orders
-
Penny stock under Rs 50: This facade system company bags new order worth Rs 2,19,48,000 from Britomatics India Pvt Ltd
-
Penny Stock Under Rs 100: Cables & Conductors Company Bags Orders Worth Rs 230,26,45,051 From Rajesh Power Services Ltd & Adani Electricity Mumbai Ltd
-
39:20 Rights Issue & 1:1 Bonus Share: Textile Penny Stock Below Rs 2 Bags Order Worth Rs 12,00,00,000 From Reputed University Based in Kota, Rajasthan
-
Penny Stock Below Rs 2 Hits Back-to-Back Upper Circuits After Announcing 61:50 Rights Issue & Rs 182.7 Crore Agreement with US-Based Pharma Company